Scientists from the Institute of Biology of the State University of Campinas (IB-UNICAMP) in Brazil and the University of Washington Medical School (WUSM) in the USA have found that inhibitor molecules suppressing the specific protein IL-22BP can positively affect the composition of the intestinal microbiota and determine the body's response to bacterial infection. The results of the study are published in the journal Proceedings of the National Academy of Sciences (PNAS)
Experts have found that IL-22BP (interleukin 22 binding protein) reduces the amount of available IL-22, a protein that helps maintain the intestinal barrier, strengthen intestinal mucosa cells and participate in the production of antimicrobial substances. Mice that do not produce IL-22BP showed increased protection against intestinal infections caused by the bacteria Clostridioides difficile and Citrobacter rodentium.
In addition, in a series of experiments, the researchers found that the composition of the gut microbiota was changed in mice without IL-22BP. The transfer of these bacteria to mice with normal IL-22BP production also resulted in protection against infection. This indicates that the absence of the IL-22BP molecule leads to beneficial changes in the microbiota.
Infection resistance is associated with increased production of short-chain fatty acids, which have beneficial effects on intestinal health, including creating an anti-inflammatory environment and strengthening the intestinal barrier. These acids are produced by intestinal bacteria during the fermentation of dietary fibers.
Further research will focus on the efficacy of IL-22BP inhibitors in animal models and in clinical trials for the treatment of severe intestinal infections. It will also investigate how different types and amounts of dietary fiber affect the production of short-chain fatty acids.